Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.

@article{Goss2014EffectsOA,
  title={Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.},
  author={Paul E Goss and Dawn L. Hershman and Angela M W Cheung and James N. Ingle and Sundeep Khosla and Vered Stearns and Haji I. Chalchal and Kendrith M. Rowland and Hyman Bernard Muss and Hannah M. Linden and Judite Scher and Kathleen I. Pritchard and Catherine R. Elliott and taNja BaDoviNac-{\vC}rNjevi{\'c} and Jessica St Louis and Judith-Anne W Chapman and Lois E. Shepherd},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 4},
  pages={474-82}
}
BACKGROUND Treatment of breast cancer with aromatase inhibitors is associated with damage to bones. NCIC CTG MA.27 was an open-label, phase 3, randomised controlled trial in which women with breast cancer were assigned to one of two adjuvant oral aromatase inhibitors-exemestane or anastrozole. We postulated that exemestane-a mildly androgenic steroid-might have a less detrimental effect on bone than non-steroidal anastrozole. In this companion study to MA.27, we compared changes in bone mineral… CONTINUE READING